Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?

However, the two market leaders could have significant competition on the way. Roche Holding (RHHBY 0.23%) underscored this last week with a major clinical study update. Shares of Lilly and Novo Nordisk fell on the news, while Roche's shares jumped nearly 6%. Could Roche be the obesity drug stock to really watch? Patients receiving CT-996 experienced weight loss of 7.3% after four weeks of treatment. Roche stated this result was "clinically meaningful" compared to the 1.2% weight loss for patients receiving ...